|
CMS organizes MEDCAC meeting to assess ESAs in transplant patients |
 |
 |
|
CMS: Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis: The Impact of ESA Use on Renal Transplant Graft Survival ........................... CMS has called this meeting of the panel to review the available evidence on the use of erythropoiesis stimulating agents (ESAs) to affect renal (kidney) transplant graft survival in patients who have both chronic kidney disease (CKD) and anemia. Some parties claim that prior ESA use may predict the long term success of subsequent renal transplantation in patients with CKD.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
